A detailed history of Jpmorgan Chase & CO transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 677 shares of ALGS stock, worth $6,478. This represents 0.0% of its overall portfolio holdings.

Number of Shares
677
Previous 677 -0.0%
Holding current value
$6,478
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$0.89 - $28.0 $2,781 - $87,500
-3,125 Reduced 82.19%
677 $1,000
Q3 2022

Nov 14, 2022

BUY
$1.06 - $27.5 $2,363 - $61,325
2,230 Added 141.86%
3,802 $5,000
Q2 2022

Aug 11, 2022

SELL
$1.04 - $2.14 $13,626 - $28,038
-13,102 Reduced 89.29%
1,572 $2,000
Q1 2022

May 11, 2022

BUY
$2.08 - $12.2 $605 - $3,550
291 Added 2.02%
14,674 $31,000
Q4 2021

Feb 10, 2022

SELL
$11.48 - $17.69 $14,935 - $23,014
-1,301 Reduced 8.3%
14,383 $170,000
Q3 2021

Nov 12, 2021

BUY
$14.57 - $17.72 $228,515 - $277,920
15,684 New
15,684 $244,000

Others Institutions Holding ALGS

About Aligos Therapeutics, Inc.


  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $380M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.